After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Chengdu Kanghong's KH815 enters human testing this month.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
AACR approaches, along with ASCO abstract titles.
A biliary tract cancer trial hits on response rate, but survival data will be key.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
